Immix Biopharma, Inc. IMMX Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s accounts payable and other current liabilities (note 11)?
- Immix Biopharma, Inc. (IMMX) reported accounts payable and other current liabilities (note 11) of $10.41M in Q1 2026.
- How has Immix Biopharma, Inc.'s accounts payable and other current liabilities (note 11) changed year-over-year?
- Immix Biopharma, Inc.'s accounts payable and other current liabilities (note 11) increased by 12.7% year-over-year, from $9.24M to $10.41M.
- What is the long-term trend for Immix Biopharma, Inc.'s accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s accounts payable and other current liabilities (note 11) has grown at a 108.6% compound annual growth rate (CAGR), from $252.34K to $9.97M.